Latest news

ABAC AbYlink Acteon afabicin (Debio 1450) afabicin (Debio 1450) ABSSSI afabicin (Debio 1450) Bone & joint infections altis labs Antibody Drug Conjufates Aspen Award BC Platforms Biocartis Campus après-demain CARB-X Carbonex CDiff Challenge Debiopharm-Inartis Clinical Trials Coorpacademy CPP cyclosporin A Debio 0123 Debio 0228 Debio 025 Debio 0432 Debio 0507 Debio 0513 Debio 0517 Debio 0614 (istaroxime) Debio 0615 Debio 0617 Debio 0719 Debio 0824 Debio 0826 Debio 0827 Debio 0928 Debio 0929 Debio 0930 Debio 0931 Debio 0932 NSCLS Debio 0932 RCC Debio 1036 Debio 1124 Debio 1124 SCLC Debio 1141 Debio 1142 Debio 1143 Debio 1143 Head & neck cancer Debio 1143 NSCLC Debio 1143 Ovarian cancer Debio 1143 selected solid tumors Debio 1143 with pembrolizumab Debio 1144 Debio 1347 Debio 1348 Debio 1449 Debio 1453 Debio 1454 Debio 1454M Debio 1454S Debio 1460 Debio 1561 Debio 1562 Debio 4126 Debio 8206 SC Debio 8609 Sanvar Debio 9902 - ZT-1 Debiopharm Academy Debiopharm Chair in Family Philanthropy Debiopharm Life Sciences Award Debiovision Degraducer Dexa Medica Diagnoplex EPFL EPI-hNE4 FibroTrap Fosanis fuze Galiena Capital genepoc genialis Groupe Bertrand H3 Pharma Haut-Lac HES-SO Huperzine-A IDEAL Iktos Immunexpress InnoCentive JCA-Mauvernay Award Kaiku Health KeyLemon little green house Mekonos Moapar Multilink Muscular Dystrophy naratuximab emtansine (Debio 1562) NeoVacs Novadiscovery nucleai Oncolifestyle Oncology Chair oncomfort Oxaliplatin paper.li PLGA Prix Debiopharm/Valais revogene Skiioo Spinomix Swiss Biotech Association Téléthon Tremelimumab Triptorelin VeriSIM Life VivoSense Wazoku WhiteLab Genomics xevinapant YonaLink

June 1, 2023

Debiopharm Shares Oncology Program Updates at ASCO 2023 for Novel WEE1 Inhibitor, and First-In-Class CA IX Theranostic Approach

May 30, 2023

Debiopharm Launches Phase 1 Research in Small Cell Lung Cancer with WEE1 inhibitor Debio 0123 to Outsmart DDR

May 17, 2023

Debiopharm Launches Phase 1/2 Combination Trial Investigating Brain-Penetrant Selective WEE1 Inhibitor for Brain Cancer Patients

December 16, 2021

Debiopharm further explores the potential of its potent, highly selective WEE1 inhibitor Debio 0123 in phase 1 cancer study

September 17, 2020

Debiopharm to Present Late Breaking Head & Neck Cancer Abstract at the 2020 European Society Of Medical Oncology Congress

March 5, 2020

Debiopharm Advances into the Highly Anticipated Clinical Phase for their Potent WEE1 Inhibitor

April 1, 2019

Debiopharm releases results of 3 key oncology compound programs at the 2019 American Association for Cancer Research (AACR) Conference in…

June 20, 2017

Almac Discovery and Debiopharm International SA Announce a Licensing Agreement for the Development of a Novel Wee-1 Inhibitor